Document:

Form of Subscription Agreement relating to the Series C financing

 Exhibit 10.5 
 

 
 Subscription Agreement 
 

 

 SUBSCRIPTION AGREEMENT 
 Coronado Biosciences, Inc. 
 45 Rockefeller Plaza, Suite 2000 

New York NY 10111 
 Attn: Bobby W. Sandage, Jr.,
Ph.D., CEO 
 Ladies and Gentlemen: 

1. Subscription. The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from
Coronado Biosciences, Inc., a Delaware corporation (the “Company”), the number of shares of Series C preferred stock par value $0.001 per share (the “Securities” or “Series C Preferred”) of the
Company set forth on the signature page hereof at a purchase price of $5.59 per Share. This subscription is submitted to you in accordance with and subject to the terms and conditions described in this Subscription Agreement and the Confidential
Offering Memorandum, dated May 23, 2011, as may amended or supplemented from time to time, including all attachments, schedules and exhibits thereto (the “Memorandum,” and, together with this Subscription Agreement, the
“Offering Documents”) and relating to the offering (the “Offering”) by the Company of a minimum of $2,000,000 (the “Minimum Offering”) and a maximum of $10,000,000) (the “Maximum
Offering”) of Securities, with the right at the sole discretion of the Company and the Placement Agent to increase the maximum by an additional $12,000,000 of Securities. The Securities are being offered on an exclusive basis through
National Securities Corporation (the “Placement Agent”). The minimum subscription for a Purchaser in the Offering is $50,000; provided, however, that Placement Agent and the Company, in their sole discretion, may waive
such minimum subscription requirement from time to time. 
 2. Payment. The Purchaser encloses herewith a check payable to, or will
immediately make a wire transfer payment to “Signature Bank, Escrow Agent for Coronado Biosciences, Inc.” in the full amount of the purchase price of the Securities being subscribed for. Such funds will be held for the
Purchaser’s benefit, and will be returned promptly, without interest or offset if this Subscription Agreement is not accepted by the Company or the Offering is terminated pursuant to its terms or by the Company or the Placement Agent. Together
with a check for, or wire transfer of, the full purchase price, the Purchaser is delivering (i) a completed and executed Signature Page to this Subscription Agreement and (ii) an Investor Questionnaire and Investor Profile, which is
annexed hereto. 
 3. Deposit of Funds. All payments made as provided in Section 2 hereof shall be deposited by the Company or the
Placement Agent as soon as practicable with the Escrow Agent, in a non-interest-bearing escrow account (the “Escrow Account”) until the earliest to occur of (a) the occurrence of a closing, the first of which shall not occur
until at least $2,000,000 of Securities are sold (the “First Closing”), (b) the rejection of such subscription, or (c) the termination of the Offering by the Company or the Placement Agent. The Company and the Placement
Agent may continue to offer and sell the Securities and conduct additional closings (each, a “Closing”) for the sale of additional Securities after the First Closing and until the termination of the Offering. In the event that the
Company does not effect a Closing, on or before June 30, 2011 (the “Initial Offering Period”), which period may be extended by the Company and the Placement Agent, in their mutual discretion to a date no later than
August 31, 2011 (the “Termination Date”, with this additional period, together with the Initial Offering Period, being referred to herein as the “Offering Period”), the Company will refund all subscription
funds, without deduction and/or interest accrued thereon, and will return the subscription documents to each Purchaser. If the Company and/or the Placement Agent rejects a subscription, either in whole or in part (which decision is 

in their sole discretion), the rejected subscription funds or the rejected portion thereof will be returned promptly to such Purchaser without interest
accrued thereon. 

 4. Acceptance of Subscription. The Purchaser understands and agrees that the Company and the
Placement Agent, in their discretion reserve the right to accept or reject this or any other subscription for Securities, in whole or in part, notwithstanding prior receipt by the Purchaser of notice of acceptance of this or any other subscription.
The Company shall have no obligation hereunder until the Company shall execute and deliver to the Placement Agent (on behalf of the Purchaser) an executed copy of this Subscription Agreement. If this subscription is rejected in whole, or the
Offering is terminated, all funds received from the Purchaser will be returned without interest, penalty, expense or deduction, and this Subscription Agreement shall thereafter be of no further force or effect. If this subscription is rejected in
part, the funds for the rejected portion of this subscription will be returned without interest, penalty, expense or deduction, and this Subscription Agreement will continue in full force and effect to the extent this subscription was accepted.

 5. Representations and Warranties of the Purchaser. The Purchaser hereby acknowledges, represents, warrants, and agrees as follows:

 (a) None of the Securities offered pursuant to the Offering Documents are registered under the Securities Act of 1933, as
amended (the “Securities Act”), or any state securities laws. The Purchaser understands that the offering and sale of the Securities contemplated hereby is intended to be exempt from registration under the Securities Act, by virtue
of Section 4(2) thereof and the provisions of Regulation D promulgated thereunder, based, in part, upon the truth and accuracy of, and compliance with, representations, warranties and agreements of the Purchaser contained in this Subscription
Agreement; 
 (b) The Purchaser and the Purchaser’s attorney, accountant, purchaser representative and/or tax advisor, if
any (collectively, the “Advisors”), acknowledges that it has received the Offering Documents, either in hard copy or electronically, and all other documents requested by the Purchaser, has carefully reviewed them and understands the
information contained therein, and the Purchaser and the Advisors, if any, prior to the execution of this Subscription Agreement, have had access to the same kind of information as would be available in a registration statement filed by the Company
under the Securities Act. Purchaser’s decision to enter into this Subscription Agreement and the other Transaction Documents (as defined herein) has been made based solely on the independent evaluation of the Purchaser and its Advisors, if any;

 (c) Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission or other
regulatory body has approved the Securities or passed upon or endorsed the merits of the Offering or confirmed the accuracy or determined the adequacy of the Offering Documents. Any representation to the contrary is a criminal offense. The Offering
Documents have not been reviewed by any federal, state or other regulatory authority. The Securities, and the shares of common stock issuable upon conversion of the Series C Preferred (the “Conversion Shares”) are subject to
restrictions on transferability and resale and may not be transferred or resold except as permitted under the Securities Act, and the applicable state securities laws, pursuant to registration or exemption therefrom; 

(d) All documents, records, and books pertaining to the investment in the Securities (including, without limitation, the Offering
Documents) have been made available, subject to certain confidentiality restrictions, for inspection by the Purchaser and its Advisors, if any; 
 (e) The Purchaser and its Advisors, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or persons acting on behalf of the Company concerning the offering of
the Securities and the business, financial condition, and results of operations of the Company, and all such questions have been answered by representatives of the Company to the full satisfaction of the Purchaser and its Advisors, if any;

  
 2 

 (f) In evaluating the suitability of an investment in the Company, the Purchaser has not
relied upon any representation or other information (oral or written) other than as stated in the Offering Documents or as contained in documents so furnished to the Purchaser or its Advisors, if any, by the Company or the Placement Agent;

 (g) The Purchaser is unaware of, is in no way relying on, and did not become aware of the Offering directly or indirectly
through or as a result of, any form of general solicitation or general advertising including, without limitation, any press release, filing with the SEC, article, notice, advertisement or other communication published in any newspaper, magazine or
similar media or broadcast over television, radio or the internet and is not subscribing for Securities and did not become aware of the Offering through or as a result of any seminar or meeting to which the Purchaser was invited by, or any
solicitation of a subscription by, a person not previously known to the Purchaser in connection with investments in securities generally; 
 (h) The Purchaser has taken no action which would give rise to any claim by any person for brokerage commissions, finder’ fees or the like relating to this Subscription Agreement or the transactions
contemplated hereby (other than commissions and other compensation to be paid by the Company to the Placement Agent or as otherwise described in the Offering Documents); 
 (i) The Purchaser’s decision to enter into this Subscription Agreement has been made based solely on the independent evaluation of the Purchaser and its own Advisors, if any, and the Purchaser,
either alone or together with its Advisors, if any, has such knowledge and experience in financial, tax, and business matters, and, in particular, investments in securities, so as to enable it to utilize the information made available to it in
connection with the Offering to evaluate the merits and risks of an investment in the Securities and the Company and to make an informed investment decision with respect thereto; 

(j) The Purchaser is not relying on the Company, the Placement Agent or any of their respective employees or agents with respect to the
legal, tax, economic and related considerations of an investment in the Securities, and the Purchaser has relied on the advice of, or has consulted with, only its own Advisors, if any; 

(k) The Purchaser is neither a registered representative under the Financial Industry Regulatory Authority (“FINRA”), a
member of FINRA or associated or affiliated with any member of FINRA, nor a broker-dealer registered with the SEC under the Exchange Act or engaged in a business that would require it to be so registered, nor is it an affiliate of a such a
broker-dealer or any person engaged in a business that would require it to be registered as a broker-dealer. In the event such Purchaser is a member of FINRA, or associated or affiliated with a member of FINRA, such Purchaser agrees, if requested by
FINRA, to sign a lock-up, the form of which shall be satisfactory to FINRA with respect to the Securities. Furthermore, the Purchaser is not an underwriter of the Securities, nor is it an affiliate of an underwriter of the Securities. 

(l) The Purchaser is acquiring the Securities solely for such Purchaser’s own account for investment purposes only and not with a
view to or intent of resale or distribution thereof, in whole or in part. The Purchaser has no agreement or arrangement, formal or informal, with any person to sell or transfer all or any part of the Securities, and the Purchaser has no plans to
enter into any such agreement or arrangement; 

  
 3 

 (m) The purchase of the Securities represents a high risk capital investment and the
Purchaser is able to afford an investment in a speculative venture having the risks and objectives of the Company and is in a position to sustain a loss of their entire investment. The Purchaser must bear the substantial economic risks of the
investment in the Securities indefinitely because none of the Securities or the Conversion Shares may be sold, hypothecated or otherwise disposed of unless subsequently registered under the Securities Act and applicable state securities laws or an
exemption from such registration is available. Legends shall be placed on the Securities and the Conversion Shares to the effect that they have not been registered under the Securities Act or applicable state securities laws and appropriate
notations thereof will be made in the Company’s books. Stop transfer instructions will be placed with the transfer agent of the Securities, if any, or with the Company. There can be no assurance that there will be any market for resale of the
Series C Preferred or the Conversion Shares. The Company has agreed that purchasers of the Securities will have, with respect to the Conversion Shares, the registration rights described herein; 

(n) The Purchaser has adequate means of providing for such Purchaser’s current financial needs and foreseeable contingencies and has
no need for liquidity of its investment in the Securities for an indefinite period of time; 
 (o) The Purchaser is aware that
an investment in the Securities involves a number of very significant risks and has carefully read and considered the matters set forth under the caption “Risk Factors” in the Offering Documents, and, in particular, acknowledges that the
Company has a limited operating history and limited assets, the Company has not had any revenues from product sales to date, the Company has incurred loses since its inception, and the Company is engaged in a highly competitive business; 

(p) The Purchaser meets the requirements of at least one of the suitability standards for an “accredited investor” as that term
is defined in Regulation D under the Securities Act, and has truthfully and accurately completed the Investor Questionnaire attached hereto; 
 (q) The Purchaser: (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to execute and deliver this Subscription Agreement and all other
related agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or association, joint stock company, trust, unincorporated organization or
other entity, represents that such entity was not formed for the specific purpose of acquiring the Securities, such entity is duly organized, validly existing and in good standing under the laws of the state of its organization, the consummation of
the transactions contemplated hereby is authorized by, and will not result in a violation of any law applicable to it or its charter or other organizational documents, such entity has full power and authority to execute and deliver this Subscription
Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the Securities and the Securities, the execution and delivery of this Subscription Agreement has been duly
authorized by all necessary action, this Subscription Agreement has been duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this Subscription Agreement in a
representative or fiduciary capacity, represents that it has full power and authority to execute and deliver this Subscription Agreement in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or
limited liability company or partnership, or other entity for whom the Purchaser is executing this Subscription Agreement, and such individual, partnership, ward, trust, estate, corporation, or limited liability company or partnership, or other
entity has full right and power to perform pursuant to this Subscription Agreement and make an investment in the Company, and represents that this Subscription Agreement constitutes a legal, valid and binding obligation of such entity. The execution
and delivery of this Subscription Agreement will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document to which the Purchaser is a party or by which it is bound; 

  
 4 

 (r) The Purchaser and the Advisors, if any, have had the opportunity to obtain any
additional information, to the extent the Company had such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy of the information contained in the Offering Documents and all
documents received or reviewed in connection with the purchase of the Securities and have had the opportunity to have representatives of the Company provide them with such additional information regarding the terms and conditions of this particular
investment and the financial condition, results of operations, business and prospects of the Company deemed relevant by the Purchaser or the Advisors, if any, and all such requested information, to the extent the Company had such information in its
possession or could acquire it without unreasonable effort or expense, has been provided by the Company to the full satisfaction of the Purchaser and the Advisors, if any; 
 (s) Any information which the Purchaser has heretofore furnished or is furnishing herewith to the Company or the Placement Agent is complete and accurate and may be relied upon by the Company and the
Placement Agent in determining the availability of an exemption from registration under Federal and state securities laws in connection with the Offering. The Purchaser further represents and warrants that it will notify and supply corrective
information to the Company and the Placement Agent immediately upon the occurrence of any change therein occurring prior to the Company’s issuance of the securities underlying the Securities; 

(t) The Purchaser has significant prior investment experience, including investments in high risk securities. The Purchaser is
knowledgeable about investments in small and thinly capitalized, development stage companies. The Purchaser has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such a loss should occur. The
Purchaser’s overall commitment to investments which are not readily marketable is not excessive in view of the Purchaser’s net worth and financial circumstances and the purchase of the Securities will not cause such commitment to become
excessive. The investment is a suitable one for the Purchaser; 
 (u) The Purchaser is satisfied that it has received adequate
information with respect to all matters which it or the Advisors, if any, consider material to its decision to make this investment; 
 (v) The Purchaser acknowledges that any estimates or forward-looking statements or projections included in the Offering Documents were prepared by the Company in good faith but that the attainment of any
such projections, estimates or forward-looking statements cannot be guaranteed and will not be updated by the Company and should not be relied upon; 
 (w) No oral or written representations have been made, or oral or written information furnished, to the Purchaser or its Advisors, if any, in connection with the Offering which are in any way inconsistent
with the information contained in the Offering Documents; 
 (x) Within five (5) business days after receipt of a request
from the Company or the Placement Agent, the Purchaser will provide such information and deliver such documents as may reasonably be necessary to comply with any and all laws and ordinances to which the Company or the Placement Agent is subject;

 (y) The Purchaser’s substantive relationship with the Company, the Placement Agent or subagent through which the
Purchaser is subscribing for Securities predates the Company’s, Placement Agent’s or such subagent’s contact with the Purchaser regarding an investment in the Securities; 

  
 5 

 (z) THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR THE SECURITIES LAWS OF ANY STATES AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY
NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES
COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE OFFERING DOCUMENTS. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL;

 (aa) The Purchaser understands that affiliates and/or employees of the Placement Agent (i) will receive the compensation
set forth elsewhere in the Offering Documents in connection with the Offering, and (ii) may, but are not obligated to, purchase Securities in the Offering and any and all such Securities purchased shall be counted toward the Minimum Offering
and the Maximum Offering. 
 (bb) (For ERISA plans only) The fiduciary of the ERISA plan represents that such fiduciary
has been informed of and understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of
ERISA that require diversification of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible for the decision to invest in the Company; (b) is independent of the Company or any of its
affiliates; (c) is qualified to make such investment decision; and (d) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation of the Company or any of its affiliates; 

(cc) The Purchaser should check the Office of Foreign Assets Control (“OFAC”) website at
<http://www.treas.gov/ofac> before making the following representations. The Purchaser represents that the amounts invested by it in the Company in the Offering were not and are not directly or indirectly derived from activities that
contravene federal, state or international laws and regulations, including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by OFAC prohibit, among other things, the engagement in transactions with,
and the provision of services to, certain foreign countries, territories, entities and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at <http://www.treas.gov/ofac>. In
addition, the programs administered by OFAC (the “OFAC Programs”) prohibit dealing with
individuals1 or entities in certain countries regardless
of whether such individuals or entities appear on the OFAC lists; 
 (dd) To the best of the Purchaser’s knowledge, none
of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser
is acting as agent or nominee in connection with this investment is a country, territory, individual or entity named on an OFAC list, or a person or entity prohibited under the OFAC Programs. Please be advised that the Company may not accept any
amounts from a prospective investor if such prospective investor cannot make the representation set forth in the preceding paragraph. The Purchaser agrees to promptly notify the Company and the Placement Agent should the Purchaser become aware of
any change in the information 
  
  

	1 	 These individuals include specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and
embargo programs. 

  
 6 

 set forth in these representations. The Purchaser understands and acknowledges that, by law, the Company may
be obligated to “freeze the account” of the Purchaser, either by prohibiting additional subscriptions from the Purchaser, declining any redemption requests and/or segregating the assets in the account in compliance with governmental
regulations, and the Placement Agent may also be required to report such action and to disclose the Purchaser’s identity to OFAC. The Purchaser further acknowledges that the Company may, by written notice to the Purchaser, suspend the
redemption rights, if any, of the Purchaser if the Company reasonably deems it necessary to do so to comply with anti-money laundering regulations applicable to the Company and the Placement Agent or any of the Company’s other service
providers. These individuals include specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo programs; 

(ee) To the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling
or controlled by the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or nominee in connection with this
investment is a senior foreign political figure2, or any
immediate family3 member or close associate4 of a senior foreign political figure, as such terms are defined in
the footnotes below; and 
 (ff) If the Purchaser is affiliated with a non-U.S. banking institution (a “Foreign
Bank”), or if the Purchaser receives deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser represents and warrants to the Company that: (1) the Foreign Bank has a
fixed address, other than solely an electronic address, in a country in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records related to its banking activities; (3) the Foreign
Bank is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not have a physical presence in
any country and that is not a regulated affiliate. 
 (gg) The Purchaser understands, acknowledges, covenants and agrees that
until the time immediately prior to the declaration or ordering of effectiveness of a Form S-1 (as defined in the Memorandum) by the SEC neither the Purchaser nor any of its affiliates nor any entity managed or controlled by the Purchaser will ever
(i) enter into or execute or cause any person or entity to enter into or execute any “short sale” (as such term is defined in Rule 200 of Regulation SHO or any successor regulation promulgated by the SEC under the Securities Exchange
Act of 1934, as amended (the “Exchange Act”)) of Series C Preferred, Common Stock or any other equity securities of the Company or (ii) engage, through related parties or otherwise, in any derivative or hedging transaction
directly related to the Company’s equity securities (including, without limitation, the purchase of any option or contract to sell). Further, Purchaser agrees that, upon the reasonable request of the Company, Purchaser will, and it will use its
best efforts to cause its affiliates or any entity managed or controlled by the Purchaser to, verify in writing to the Company that it has not engaged in any such short sale, derivative hedging transaction directly related to such securities.

  
  

	2 	 A “senior foreign political figure” is defined as a senior official in the executive, legislative, administrative, military or judicial
branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government-owned corporation. In addition, a “senior foreign political figure” includes any
corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign political figure. 

	3 	 “Immediate family” of a senior foreign political figure typically includes the figure’s parents, siblings, spouse, children and in-laws.

	4 	 A “close associate” of a senior foreign political figure is a person who is widely and publicly known to maintain an unusually close
relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial domestic and international financial transactions on behalf of the senior foreign political figure.

  
 7 

 6. Representations, Warranties and Covenants of the Company. The Company hereby represents, warrants,
acknowledges and agrees as follows: 
 (a) Organization, Good Standing and Qualification. (a) The Company is duly
organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority to own, lease, use and operate its properties and to carry on its business as and where now owned, leased,
used, operated and conducted. The Company has no subsidiaries. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership or use of property or the nature of the
business conducted by it makes such qualification necessary except where the failure to be so qualified or in good standing would not have a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial or
otherwise), business, or prospects of the Company or (ii) the ability of the Company to perform its obligations under the Transaction Documents (as defined below) (a “Material Adverse Effect”). 

(b) Authorization; Enforceability. The Company has all corporate power and authority to (i) enter into and perform its
obligations under this Agreement and the other agreements contemplated hereby (this Agreement and the other agreements contemplated hereby, are collectively referred to herein as the “Transaction Documents”), (ii) issue, sell
and deliver the Securities and (iii) issue, sell and deliver the Conversion Shares. The execution and delivery of this Agreement and the other Transaction Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby, have been duly authorized by the Company’s Board of Directors. This Agreement has been duly authorized, executed and delivered and constitutes, and each of the other Transaction Documents, upon due execution and
delivery, will constitute, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms (i) except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other similar laws now or hereafter in effect related to laws affecting creditors’ rights generally, including the effect of statutory and other laws regarding fraudulent conveyances and preferential transfers, and except that no
representation is made herein regarding the enforceability of the Company’s obligations to provide indemnification and contribution remedies under the securities laws and (ii) subject to the limitations imposed by general equitable
principles (regardless of whether such enforceability is considered in a proceeding at law or in equity). 
 (c)
Capitalization and Voting Rights. The authorized, issued and outstanding capital stock of the Company is as set forth in the Memorandum and all issued and outstanding shares of the Company are validly issued, fully paid and nonassessable.
Except as set forth in the Memorandum, there are no outstanding options, warrants, agreements, convertible securities, preemptive rights or other rights to subscribe for or to purchase any shares of capital stock of the Company. Except as set forth
in the Offering Documents and as otherwise required by law, there are no restrictions upon the voting or transfer of any of the shares of capital stock of the Company pursuant to the Company’s certificate of incorporation, bylaws or any
agreement or other instruments to which the Company is a party or by which the Company is bound. 
 (d) Disclosure. The
information set forth in the Offering Documents as of the date thereof contains no untrue statement of a material fact nor omits to state a material fact necessary in order to make the statements contained therein, in light of the circumstances
under which they were made, not misleading. 

  
 8 

 (e) Form 10 Registration Statement. The Coronado has agreed to use its commercially
reasonable efforts to file a Form 10 registration statement within sixty (60) days following the Final Closing (the “Filing Date”). In the event that the Form 10 is not filed by the Filing Date, the Company will incur monthly
liquidated damages, payable to Investors in cash, in an amount equal to one (1.0%) percent of the purchase price of the Securities until the Form 10 is filed (but in no event will the maximum aggregate liquidated damages payable exceed ten
(10%) percent). 
 7. Registration Rights. Purchaser shall have the registration rights described below. 

(a) Definitions. As used in the Subscription Agreement, the following terms shall have the following meanings. 

(1) The term “Holder” shall mean any holder of Registrable Securities. 

(2) The term “Other Registrable Securities” shall mean shares of Common Stock other than the Registrable Securities that have
registration rights senior to, or pari passu with, the Registrable Securities. 
 (3) The term “Public Date” shall
mean the first day that shares of the Company’s capital stock are registered pursuant to Section 12 of the Exchange Act 
 (4) The terms “register”, “registered” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance
with the Securities Act, and the declaration or order of effectiveness of such registration statement or document. 
 (5) The
term “Registrable Securities” shall mean (i) the shares of Common Stock issuable upon conversion of the Series C Preferred (or any successor security) sold in the Offering; and (ii) any shares of Common Stock issuable (or
issuable upon the conversion or exercise of any warrant, right or other security that is issued) pursuant to a dividend or other distribution with respect to or in replacement of any Securities; provided, however, that securities shall only be
treated as Registrable Securities if and only for so long as they (A) have not been disposed of pursuant to a registration statement declared effective by the SEC; (B) have not been sold in a transaction exempt from the registration and
prospectus delivery requirements of the Securities Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale; (C) are held by a Holder or a permitted transferee of a Holder
pursuant to Section 7(k); and (D) may not be disposed of under Rule 144 under the Securities Act without restriction. 

(6) The term “Trading Event” means the first date on which the Company’s common stock trades on a national securities
exchange or the OTCQX, the OTCBB, or any other market quoted by the Pink Sheets LLC, OTC Markets (or any successors to any of the foregoing). 
 (b) Piggyback Registration. 
 (1) The Company agrees that if, at any time,
and from time to time, after the earlier to occur of (i) an initial public offering of the Company’s equity securities (“IPO”) and (ii) a Trading Event, the Board of Directors of the Company (the “Board”) shall
authorize the filing of a registration statement under the Securities Act (other than the IPO or a registration statement on Form S-8, Form S-4 or any other form that does not include substantially the same information as would be required in a form
for the general registration of securities) in connection with the proposed offer of any of its securities by it or any of its stockholders, the Company shall: (A) promptly notify each Holder that such registration statement will be filed and
that the Registrable Securities then held by such Holder will be included in 

  
 9 

 
such registration statement at such Holder’s request; (B) cause such registration statement to cover all of such Registrable Securities issued to such Holder for which such Holder
requests inclusion; (C) use reasonable best efforts to cause such registration statement to become effective as soon as practicable; and (D) take all other reasonable action necessary under any Federal or state law or regulation of any
governmental authority to permit all such Registrable Securities that have been issued to such Holder to be sold or otherwise disposed of, and will maintain such compliance with each such Federal and state law and regulation of any governmental
authority for the period necessary for such Holder to promptly effect the proposed sale or other disposition. 
 (2)
Notwithstanding any other provision of this Section 7(b), the Company may at any time, abandon or delay any registration commenced by the Company. In the event of such an abandonment by the Company, the Company shall not be required to continue
registration of shares requested by the Holder for inclusion, the Holder shall retain the right to request inclusion of shares as set forth above and the withdrawn registration shall not be deemed to be a registration request for the purposes of
Section 7(b)(3) below. 
 (3) Each Holder shall have the right to request inclusion of any of its Registrable Securities in
a registration statement as described in this Section 7(b) up to two times. 
 (c) Automatic Registration rights.

 (1) In addition to the registration rights set out above, within 60 days of the Public Date, the Company shall file a resale
registration statement covering the resale of the common stock issuable upon conversion of the Series C Preferred (or less than all, if the Company is limited in the number of shares that it can include on such resale registration statement by
regulation or the requirements of any exchange), and use its commercially reasonable efforts to have the registration statement declared effective within 120 days after the Public Date. In the event that the registration statement is not filed
within 60 days of the Public Date, the Company will incur monthly liquidated damages, payable to Investors in cash, in an amount equal to one (1.0%) percent of the purchase price of the Series C Preferred until the registration statement is
filed (but in no event will the maximum aggregate liquidated damages payable exceed ten (10%) percent). 
 (d) Demand
Registration. 
 (1) Registration on Request. 

(i) The Company agrees that if, at any time, and from time to time, but at least 180 days after the earlier of (i) the effective
date of an initial offering of Coronado’s equity securities pursuant to an effective registration statement and (ii) a Trading Event, Holders of a majority of the Registrable Securities may make a written request that the Company effect
the registration under the Securities Act of outstanding Registrable Securities; provided that such requested registration would cover at least 51% of the Registrable Securities owned by all the Holders at such time; and provided,
further, that the Holders shall be entitled to no more than one such demand registration. 
 (ii) The Company further
agrees that if, at any time, and from time to time, after the Company has qualified for the use of Form S-3 or any successor form, and ending on the date that is five years from the final Closing, one or more of the Holders desire to effect the
registration under the Securities Act on Form S-3 or any successor form (“Short-Form Registration”) of outstanding Registrable Securities, such Holder(s) may make a written request that the Company effect a Short-Form Registration;
provided that the aggregate price to the public of the shares as to which such registration is requested (based on the then current market price and before deducting underwriting discounts and

  
 10 

 
commissions) would equal or exceed $5,000,000. It is understood and agreed that the Holders may make good faith requests for Short-Form Registrations on an unlimited number of occasions;
provided further, that the Company shall not be required to effect more than one Short Form Registration in any 12 month period. 
 (iii) Each request made by one or more of the Holders pursuant to subsections (i) or (ii) above (the “Initiating Holders”) will specify the number of shares of Registrable Securities
proposed to be sold and will also specify the intended method of disposition thereof. Following receipt of any such request, the Company shall promptly notify all Holders other than the Initiating Holders of receipt of such request and the Company
shall use best efforts to file, within 60 days of such request, the registration under the Securities Act of the Registrable Securities which the Company has been so requested to register in the request by the Initiating Holders (and in all notices
received by the Company from such other Holders within 30 days after the giving of such notice by the Company), to the extent necessary to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the Registrable
Securities to be registered. If such method of disposition shall be an underwritten public offering, the Holders of a majority of the shares of Registrable Securities to be sold in such offering may designate the managing underwriter of such
offering, subject to the approval of the Company, which approval shall not be unreasonably withheld or delayed. The Holders will be permitted to withdraw Registrable Securities from a registration at any time prior to the effective date of such
registration; provided the remaining number of shares of Registrable Securities subject to a requested registration is not less than the minimum amount required pursuant to this Section 5.3. 

(2) Limitations on Demand Registration. Notwithstanding Section 7(d)(1), 

(i) the Company shall not be obligated to file a registration statement relating to a registration request pursuant to this
Section 7(d) at any time during the 90-day period immediately following the effective date of a registration statement filed by the Company covering a firm commitment underwritten public offering of securities of the Company; and if the Board
determines, in its good faith judgment, that the Company (i) should not file any registration statement otherwise required to be filed pursuant to Section 7(d) or (ii) should withdraw any such previously filed registration statement
because the Board determines, in its good faith judgment, that the Company is in the possession of material nonpublic information required to be disclosed in such registration statement or an amendment or supplement thereto, the disclosure of which
in such registration statement would be materially disadvantageous to the Company (a “Disadvantageous Condition”), the Company shall be entitled to postpone for the shortest reasonable period of time (but not exceeding 45 days from the
date of the determination), the filing of such registration statement or, if such registration statement has already been filed, may suspend or withdraw such registration statement and shall promptly give the Holders written notice of such
determination, containing a general statement of the reasons for such postponement and an approximation of the anticipated delay. If the Company shall so postpone the filing or effect the suspension or the withdrawal of the registration statement,
the Holders who made the request for registration shall have the right to withdraw the request for registration by giving written notice to the Company within 30 days after receipt of the notice of postponement. Upon the receipt of any such notice,
such Holders shall forthwith discontinue use of the prospectus contained in such registration statement and, if so directed by the Company, shall deliver to the Company all copies of the prospectus then covering such Registrable Securities current
at the time of receipt of such notice (or, if no registration statement has yet been filed, all drafts of the prospectus covering such Registrable Securities). If any Disadvantageous Condition shall cease to exist, the Company shall promptly notify
the Holders to such effect. If any registration statement shall have been withdrawn, the Company shall, at such time as it is possible or, if earlier, at the end of the 45-day period following such withdrawal, file a new registration statement
covering the Registrable Securities that were covered by such withdrawn registration statement, and the effectiveness of such registration statement shall be maintained for such time as may be necessary

  
 11 

 
so that the period of effectiveness of such new registration statement, when aggregated with the period during which such withdrawn registration statement was effective, if any, shall be such
time as may be otherwise required by the Subscription Agreement. The Company’s right to delay a request for registration or to withdraw a registration statement pursuant to this Section 7(d) may not be exercised more than once in any
one-year period. 
 (e) Registration Procedures. Whenever required under this Section 7 to include Registrable
Securities in a Company registration statement, the Company shall, as expeditiously as reasonably possible: 
 (1) Use best
efforts to (i) cause such registration statement to become effective, and (ii) cause such registration statement to remain effective until the earliest to occur of (A) such date as the Holders selling Registrable Securities have
completed the distribution described in the registration statement and (B) such time that all of such Registrable Securities are no longer, by reason of Rule 144 under the Act, required to be registered for the sale thereof by such Holders. The
Company will also use its best efforts to, during the period that such registration statement is required to be maintained hereunder, file such post-effective amendments and supplements thereto as may be required by the Securities Act and the rules
and regulations thereunder or otherwise to ensure that the registration statement does not contain any untrue statement of material fact or omit to state a fact required to be stated therein or necessary to make the statements contained therein, in
light of the circumstances under which they are made, not misleading; provided, however, that if applicable rules under the Securities Act governing the obligation to file a post-effective amendment permits, in lieu of filing a post-effective
amendment that (i) includes any prospectus required by Section 10(a)(3) of the Securities Act or (ii) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement,
the Company may incorporate by reference information required to be included in (i) and (ii) above to the extent such information is contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the
registration statement. In the event that the Company becomes qualified for the use of Form S-3 or any successor form at a time when any registration statement on any other Form which includes Registrable Securities is required to be maintained
hereunder, the Company shall, upon the request of any selling Holder, subject to Section 7(f), (i) as expeditiously as reasonably possible, use best efforts to cause a Short-Form Registration covering such Registrable Securities to become
effective and (ii) comply with each of the other requirements of this Section 7(e) which may applicable thereto. Upon the effectiveness of such Short-Form Registration, the Company shall be relieved of its obligations hereunder to keep in
effect the registration statement which initially covered the Registrable Securities included in such Short-Form Registration. 

(2) Prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. 

(3) Make available for inspection upon reasonable notice during the Company’s regular business hours by each selling Holder, any
underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other agent retained by such selling Holder or underwriter, all financial and other records, pertinent corporate documents and
properties of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such selling Holder, underwriter, attorney, accountant or agent in connection with such registration
statement. 
 (4) Furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus as
amended or supplemented from time to time, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

  
 12 

 (5) Use best efforts to register and qualify the securities covered by such registration
statement under such other federal or state securities laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to
qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

(6) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(7) Notify each Holder of Registrable Securities covered by such registration statement, at any time when a prospectus relating thereto
is required to be delivered under the Securities Act, (i) when the registration statement or any post-effective amendment and supplement thereto has become effective; (ii) of the issuance by the SEC of any stop order or the initiation of
proceedings for that purpose (in which event the Company shall make every effort to obtain the withdrawal of any order suspending effectiveness of the registration statement at the earliest possible time or prevent the entry thereof); (iii) of
the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities for sale in any jurisdiction or the initiation of any proceeding for such purpose; and (iv) of the happening of any
event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing (and each Holder agrees to suspend any trading under the Registration Statement until such condition is abated). 

(8) Cause all such Registrable Securities registered hereunder to be listed on each securities exchange or quotation service on which
similar securities issued by the Company are then listed or quoted or, if no such similar securities are listed or quoted on a securities exchange or quotation service, apply for qualification and use best efforts to qualify such Registrable
Securities for inclusion on a national securities exchange or the OTCBB. 
 (9) Provide a transfer agent and registrar for all
Registrable Securities registered pursuant hereunder and CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 
 (10) Cooperate with the selling Holders and the managing underwriters, if any, to facilitate the timely preparation and delivery of certificates representing the Registrable Securities to be sold, which
certificates will not bear any restrictive legends; and enable such Registrable Securities to be in such denominations and registered in such names as the managing underwriters, if any, shall request at least two business days prior to any sale of
the Registrable Securities to the underwriters. 
 (e) Furnish Information. It shall be a condition precedent to the
obligation of the Company to take any action pursuant to this Section 7 with respect to the Registrable Securities of any Holder that such Holder shall furnish to the Company such information regarding the Holder, the Registrable Securities
held by the Holder, and the intended method of disposition of such securities as shall be reasonably required by the Company to effect the registration of such Holder’s Registrable Securities. 

  
 13 

 (f) Registration Expenses. The Company shall bear and pay all expenses incurred in
connection with any registration, filing or qualification of Registrable Securities with respect to registrations pursuant to Section 7 for each Holder, including (without limitation) all registration, filing, and qualification fees, printers
and accounting fees relating or apportionable thereto and fees and expenses of one counsel to the Holders to be designated by the Placement Agent (not to exceed $10,000) (“Registration Expenses”), but excluding underwriting discounts and
commissions relating to Registrable Securities and excluding any professional fees or costs of accounting, financial or legal advisors (in excess of $10,000) to any of the Holders. 

(g) Underwriting Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital
stock, the Company shall not be required under Section 7(b) to include any of the Holders’ Registrable Securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters
selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of
securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success
of the offering (the securities so included to be apportioned pro rata among the selling Holders according to the total amount of securities entitled to be included therein owned by each selling Holder or in such other proportions as shall mutually
be agreed to by such selling Holders). For purposes of the preceding parenthetical concerning apportionment, for any selling Holder who is a holder of Registrable Securities and is a partnership or corporation, the partners, retired partners and
stockholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling Holder”, and any pro-rata
reduction with respect to such “selling Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling Holder”, as defined in this sentence.

 (h) Rule 415 Requirements. Notwithstanding the registration obligations set forth in this Section 7, in the event
the SEC informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale on a single registration statement, the Company agrees to promptly (i) inform each of the Holders
thereof, (ii) use its commercially reasonable efforts to file amendments to the registration statement as required by the SEC and/or (iii) withdraw the registration statement and file a new registration statement (a “New
Registration Statement”), in either case covering the maximum number of Registrable Securities permitted to be registered by the SEC, on Form S-1 or such other form available to register for resale the Registrable Securities as a secondary
offering; provided, however, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the SEC for the registration of all of the Registrable
Securities in accordance with the SEC guidance, including without limitation, the Manual of Publicly Available Telephone Interpretations D.29. In the event the Company amends the registration statement or files a New Registration Statement, as the
case may be, under clauses (ii) or (iii) above, the Company will use its commercially reasonable efforts to file with the SEC, as promptly as allowed by the SEC or by SEC guidance provided to the Company or to registrants of securities in
general, one or more registration statements on Form S-1 or such other form available to register for resale those Registrable Securities that were not registered for resale on the registration statement, as amended, or the New Registration
Statement. The foregoing notwithstanding, if the Company is required to limit the number of shares that it can include on such resale registration statement or New Registration Statement by regulation or the requirements of the SEC or any exchange,
then, 

  
 14 

 
notwithstanding any other registration rights of the Holder, the number of Registrable Securities to be included on such registration statement and New Registration Statement shall be allocated
to the Holders and the holders of Other Registrable Securities on a pro rata basis based on the number of Registrable Securities and Other Registrable Securities held by such holders. 

(i) Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 7. 
 (j) Indemnification. In the event that any Registrable Securities are included in a registration statement under this Section 7: 

(1) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the
Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may
become subject under the Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations
(collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, or any rule or regulation promulgated under the Securities Act, or the Exchange Act, and the Company will pay to each such Holder, underwriter or controlling person, as incurred, any
legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 7(j)(1) shall not
apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any
such case for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with
such registration by any such Holder, underwriter or controlling person or a violation of any provision of the Subscription Agreement by a Holder. 
 (2) To the extent permitted by law, each Holder will indemnify and hold harmless the Company, each of its directors, each of its officers, each person, if any, who controls the Company within the meaning
of the Securities Act, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to
which any of the foregoing persons may become subject, under the Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case
to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration or a violation of any provision of the
Subscription Agreement by a Holder; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 7(j)(2), in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 7(j)(2) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, further, that, in no event shall any indemnity under this Section 7(j)(2) exceed the
greater of the cash value of the (i) gross proceeds from the offering received by such Holder or (ii) such Holder’s investment pursuant to this Subscription Agreement as set forth on the signature page attached hereto. 

  
 15 

 (3) Promptly after receipt by an indemnified party under this Section 7(j) of notice of
the commencement of any action (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party under this Section 7(j), deliver to the indemnifying party a written
notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly notified, to assume the defense thereof
with counsel selected by the indemnifying party and approved by the indemnified party (whose approval shall not be unreasonably withheld); provided, however, that an indemnified party (together with all other indemnified parties which may be
represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 7(i), but the
omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 7(j). 

(4) If the indemnification provided for in this Section 7 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection
with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the
parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 (5) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public
offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 (6) The
obligations of the Company and Holders under this Section 7(j) shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 7, and otherwise. 

(k) Reports Under Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 

(1) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after 90 days after
the effective date of the IPO or Trading Event by the Company; 

  
 16 

 (2) file with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act; and 
 (3) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (ii) such other information as may be reasonably
requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
 (l) Permitted Transferees. The rights to cause the Company to register Registrable Securities granted to the Holders by the Company under this Section 7 may be assigned in full by a Holder in
connection with a transfer by such Holder of its Registrable Securities if: (a) such Holder gives prior written notice to the Company; (b) such transferee agrees to comply with the terms and provisions of the Subscription Agreement;
(c) such transfer is otherwise in compliance with the Subscription Agreement, (d) such transfer is otherwise effected in accordance with applicable securities laws and (e) such Holder transfers at least 51% of its shares of
Registrable Securities to the transferee. Except as specifically permitted by this Section 7(l), the rights of a Holder with respect to Registrable Securities as set out herein shall not be transferable to any other person, and any attempted
transfer shall cause all rights of such Holder therein to be forfeited. 
 (m) Termination of Registration Rights The
right of any Holder to request or demand inclusion in any registration pursuant to Sections 7(b) or 7(d) shall terminate at such time as all shares of Registrable Securities held by such Holder may immediately be sold under Rule 144 without
restriction. 
 8. Indemnification. The Purchaser agrees to indemnify and hold harmless the Company, the Placement Agent, and their
respective officers, directors, employees, agents, attorneys, control persons and affiliates from and against all losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred
in investigating, preparing or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact,
or breach by the Purchaser of any covenant or agreement made by the Purchaser herein or in any other document delivered in connection with this Subscription Agreement. 
 9. Irrevocability; Binding Effect. The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser, except as required by applicable law, and that this
Subscription Agreement shall survive the death or disability of the Purchaser and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives, and permitted assigns. If
the Purchaser is more than one person, the obligations of the Purchaser hereunder shall be joint and several and the agreements, representations, warranties, and acknowledgments herein shall be deemed to be made by and be binding upon each such
person and such person’s heirs, executors, administrators, successors, legal representatives, and permitted assigns. 
 10.
Modification. Any of the terms or provisions of this Subscription Agreement shall not be modified or waived except by an instrument in writing signed by (a) the Company, (b) the Placement Agent and (c) the holders of at least a
majority of the then outstanding Securities issued in the Offering (including shares of the Company’s common stock issued upon conversion of the Securities issued the Offering), as measured at the time of such modification or waiver.
Notwithstanding the foregoing, no provision of this agreement may be modified or waived in a manner that adversely affects the specific rights or obligations of a party hereunder in a manner different than such modification or waiver affects all
other similarly situated parties without the written consent of such adversely affected party. Any 

  
 17 

 
modification or waiver effected in accordance with the provisions of this Section 10 shall be binding on all parties hereto and each party’s respective successors and permitted assigns,
whether or not such party, successor or assignee executed such modification or waiver. 
 11. Immaterial Modifications to the Transaction
Documents. The Company may, at any time prior to the First Closing, amend the Transaction Documents if necessary to clarify any provision therein, without first providing notice or obtaining prior consent of the Purchaser, if, and only if, such
modification is not material in any respect. 
 12. Notices. Any notice or other communication required or permitted to be given
hereunder shall be in writing and shall be mailed by certified mail, return receipt requested, or delivered against receipt to the party to whom it is to be given (a) if to the Company, at the address set forth above, or (b) if to the
Purchaser, at the address set forth on the signature page hereof (or, in either case, to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 13). Any notice or other communication
given by certified mail shall be deemed given at the time of certification thereof, except for a notice changing a party’s address which shall be deemed given at the time of receipt thereof. 

13. Assignability. This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the
Purchaser and the transfer or assignment of the Securities shall be made only in accordance with all applicable laws. 
 14. Applicable
Law. This Subscription Agreement shall be governed by and construed under the laws of the State of New York as applied to agreements among New York residents entered into and to be performed entirely within New York. Each of the parties hereto
(1) agree that any legal suit, action or proceeding arising out of or relating to the Subscription Agreement shall be instituted exclusively in the state or federal courts located in New York County, New York, (2) waive any objection which
they may have now or hereafter to the venue of any such suit, action or proceeding, and (3) irrevocably consent to the jurisdiction of such courts in any such suit, action or proceeding. Each of the parties hereto further agrees to accept and
acknowledge service of any and all process which may be served in any such suit, action or proceeding in such courts and agree that service of process upon it mailed by certified mail to its address shall be deemed in every respect effective service
of process upon it, in any such suit, action or proceeding. THE PARTIES HERETO AGREE TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS SUBSCRIPTION AGREEMENT OR ANY DOCUMENT OR
AGREEMENT CONTEMPLATED HEREBY. 
 15. Blue Sky Qualification. The purchase of Securities under this Subscription Agreement is expressly
conditioned upon the exemption from qualification of the offer and sale of the Securities from applicable federal and state securities laws. The Company shall not be required to qualify this transaction under the securities laws of any jurisdiction
and, should qualification be necessary, the Company shall be released from any and all obligations to maintain its offer, and may rescind any sale contracted, in the jurisdiction. 
 16. Use of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the person or persons
referred to may require. 
 17. Confidentiality. The Purchaser acknowledges and agrees that any information or data the Purchaser has
acquired from or about the Company, not otherwise properly in the public domain, was received in confidence (the “Confidential Information”). Any distribution of the Confidential Information to any person other than the Purchaser named
above, in whole or in part, or the reproduction of the 

  
 18 

 
Confidential Information, or the divulgence of any of its contents (other than to the Purchaser’s tax and financial advisers, attorneys and accountants, who will likewise be required to
maintain the confidentiality of the Confidential Information) is unauthorized, except that any Purchaser (and each employee, representative, or other agent of such Purchaser) may disclose to any and all persons, without limitations of any kind
(except as provided in the next sentence) the tax treatment and tax structure of the transaction and all materials of any kind (including opinions or other tax analyses) that are provided to the Purchaser relating to such tax treatment and tax
structure. Any such disclosure of the tax treatment, tax structure and other tax-related materials shall not be made for the purpose of offering to sell the Securities offered hereby or soliciting an offer to purchase any such securities. Except as
provided above with respect to tax matters, the above named Purchaser agrees not to divulge, communicate or disclose, except as may be required by law or for the performance of this Subscription Agreement, or use to the detriment of the Company or
for the benefit of any other person or persons, or misuse in any way, any Confidential Information of the Company, including any scientific, technical, trade or business secrets of the Company and any scientific, technical, trade or business
materials that are treated by the Company as confidential or proprietary, including, but not limited to, ideas, discoveries, inventions, developments and improvements belonging to the Company and confidential information obtained by or given to the
Company about or belonging to third parties. 
 18. Miscellaneous. 

(a) The Offering Documents, together with the Transaction Documents, constitute the entire agreement between the Purchaser and the Company
with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. 
 (b) The representations and warranties of the Company made in this Subscription Agreement shall survive the execution and delivery hereof and delivery of the Securities hereunder for a period of twelve
(12) months from the date of issuance. The representations and warranties of the Purchaser made in this Subscription Agreement shall survive the execution and delivery hereof and delivery of the Securities hereunder indefinitely.

 (c) Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants,
appraisers or others engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the transactions contemplated hereby are consummated. 

(d) This Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original, but all of which
shall together constitute one and the same instrument. 
 (e) Each provision of this Subscription Agreement shall be considered
separable and, if for any reason any provision or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or affect the remaining portions of this Subscription
Agreement. 
 (f) Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of this
Subscription Agreement as set forth in the text. 
 (g) The Purchaser understands and acknowledges that there may be multiple
Closings for the Offering. 

  
 19 

 To subscribe for Securities in the private offering of 

Coronado Biosciences, Inc. 
  

	1.	Date and Fill in the number of Securities being purchased and Complete and Sign the Subscription Agreement. 

 

	2.	Initial the Accredited Investor Certification page attached to this Subscription Agreement. 

 

	3.	Complete and return the Investor Profile and, if applicable, Wire Transfer Authorization attached to this letter. 

 

	4.	Fax all forms to Jonathan C. Rich at (212) 380-2828 and then send all signed original documents with check to: 

National Securities Corporation 

330 Madison Avenue, 18th Floor 
 New York, NY 10017 
 Attn: Jonathan C. Rich

 Tel: (212) 380-2819 

 

	5.	Please make your subscription payment payable to the order of “Signature Bank, Escrow Agent for Coronado Biosciences, Inc.”  

For wiring funds directly to the escrow account, 
 see the following instructions: 
  

					
		 	Name:	    	Signature Bank
		 	ABA Number:	    	026013576
		 	SWIFT Code:	    	SIGNUS33
		 	A/C Name:	    	Signature Bank, as Agent for
		 		    	Coronado Biosciences, Inc.
		 		    	261 Madison Avenue, New York, New York 10016
		 	A/C Number:	    	1501646462
		 	FBO:	    	Investor
Name:                                       
               
		 		    	Social Security
Number:                                     

		 		    	Address:                          
                                      

		 		    	                            
                                         
           

 Questions regarding completion of the subscription documents should be directed to 

Mr. Jonathan C. Rich at (212) 380-2841. 

  
 20 

 ANTI MONEY LAUNDERING REQUIREMENTS 

 

					
	 The USA PATRIOT Act
	  	 What is money laundering?
	  	
How big is the problem and why is it important?

	 The USA PATRIOT Act is designed to detect, deter, and punish terrorists in the United States and abroad. The Act imposes new anti-money
laundering requirements on brokerage firms and financial institutions. Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money laundering programs.

 
 To help you understand these efforts, the Placement Agent wants to provide you with
some information about money laundering and its steps to implement the USA PATRIOT Act.
	  	Money laundering is the process of disguising illegally obtained money so that the funds appear to come from legitimate sources or activities. Money laundering occurs in connection
with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.	  	The use of the U.S. financial system by criminals to facilitate terrorism or other crimes could well taint our financial markets. According to the U.S. State Department, one recent
estimate puts the amount of worldwide money laundering activity at $1 trillion a year.

  

			
	 What is the Placement Agent required to do to eliminate money
laundering?

		
	Under new rules required by the USA PATRIOT Act, the Placement Agent’s anti-money laundering program must designate a special compliance officer, set up employee training,
conduct independent audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with the new laws.	  	As part of its required program, the Placement Agent may ask you to provide various identification documents or other information. Until you provide the information or documents the
Placement Agent needs, we may not be able to effect any transactions for you.

  
 21 

 CORONADO BIOSCIENCES, INC. 

SIGNATURE PAGE TO THE 
 SUBSCRIPTION AGREEMENT 
 Subscriber hereby elects to subscribe under the Subscription
Agreement for a total of                  shares of Series C Preferred at a price of $5.59 per share (NOTE: to be completed by subscriber) and executes the
Subscription Agreement. 
 Date (NOTE: To be completed by subscriber):
                        , 2011 
  

 
 If the Purchaser is an INDIVIDUAL, and if
purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY: 
  

							
				
		 	  
	 		 	  

		 	Print Name(s)	 		 	Social Security Number(s)
				
		 	  
	 		 	  

		 	Signature(s) of Subscriber(s)	 		 	Signature
				
		 	  
	 		 	  

		 	Date	 		 	Address

 If the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST: 

 

							
				
		 	  
	 		 	  

		 	 Name of Partnership,
 Corporation, Limited
 Liability Company or Trust
	 		 	 Federal Taxpayer

Identification Number

  

									
		 	By:	 	  
	 		 	  

		 		 	Name:	 		 	State of Organization
		 		 	Title:	 		 	
				
		 	  
	 		 	  

		 	Date	 		 	Address

  

									
	CORONADO BIOSCIENCES, INC.	 		 	NATIONAL SECURITIES CORP.
					
	By:	 	  
	 		 	By:	 	  

		 	    Authorized Officer	 		 		 	    Authorized Officer

  
 22Form of Consent and Support Agreement

 Exhibit 10.6 
 CONSENT AND SUPPORT AGREEMENT 
 This CONSENT
AND SUPPORT AGREEMENT (“Agreement”) is being executed and delivered as of the date set forth on the signature page hereof, for the benefit of
CORONADO BIOSCIENCES, INC., a Delaware corporation (the “Company”), by the stockholder of the Company identified on the signature page hereof (the
“Stockholder”). 
 RECITALS 

A. The Company’s Board of Directors (the “Board”) has approved, subject to stockholder approval, an
amendment to the Company’s Amended and Restated Certificate of Incorporation, as modified by that certain Certificate of Designation, Preferences and Rights of the Series B Preferred Stock (the “Current
Certificate”) to (i) eliminate the Special Dividend set forth in Article IV.E Section 1(a) of the Current Certificate and (ii) restate the automatic conversion provision applicable to the Company’s Series A Preferred
Stock (the “Series A Preferred”) set forth in Article IV.E, Section 5(j) of the Current Certificate which, in turn, is applicable to the Company’s Series B Preferred Stock (the “Series B
Preferred”) in accordance with the terms of the Series B Preferred. Such amendment, as approved by the Board, (the “Certificate of Amendment”) is attached hereto as Exhibit A-1. 

B. The Board is currently negotiating with Kopr Resources, Inc. (“Kopr”), a public “shell”
company that is reporting pursuant to the requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with which the Company would enter into a “reverse merger” transaction (the
“Merger”). Pursuant to the Merger, it is currently contemplated that the Merger would be consummated in accordance with the terms of that certain Summary of Terms of Proposed Reverse Merger between the Company and Kopr dated
March 14, 2011, (the “Reverse Merger Term Sheet”) attached hereto as Exhibit B. 

C. As an inducement for the Stockholder to enter into this Agreement, the Board has declared, contingent upon the receipt by the
Company of executed Consent and Support Agreements from the holders of a majority of the outstanding shares of Series A Preferred, a stock dividend (the “Dividend”), contingent upon and effective and payable immediately prior
to the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware, payable in shares of the Company’s Common Stock, such that a dividend of one half (1/2) share of the Company’s Common Stock be paid
for each one (1) share of the Series A Preferred outstanding on March 1, 2011. 

AGREEMENT 
 For valuable consideration (the receipt and sufficiency of which are hereby acknowledged by Stockholder), Stockholder hereby covenants and agrees as follows: 

1. CONSENT. Stockholder hereby consents with respect to all shares of the Company’s capital stock
actually or beneficially owned by Stockholder as of the date hereof, to the adoption of the resolutions attached hereto as Exhibit A. 
 2. SUPPORT AGREEMENT; PROXY.  

 (a) Support of Merger. From and after the date on which the
Company declares the Dividend, in the event that the Board approves the Merger, Stockholder agrees to (i) be present, in person or by proxy, at all meetings for the vote thereon, (ii) vote or act by written consent with respect to all
shares of the Company’s capital stock then actually or beneficially owned by Stockholder for, and raise no objections to, such Merger; provided, that (a) such Merger is consistent with the terms of the Reverse Merger Term Sheet and
(b) the merger agreement with Kopr, the Certificate of Incorporation of Kopr and the respective Certificate of Designation for the Shares of Preferred Stock of Kopr for which the Series A Preferred and Series B Preferred will be exchanged in
the Merger (collectively, the “Merger Documents”) are acceptable to the Stockholder in form and substance, (iii) waive and refrain from exercising any dissenters’ rights, appraisal rights or similar rights that may apply
to such Merger; provided, that (a) such Merger is consistent with the terms of the Reverse Merger Term Sheet and (b) the Merger Documents are acceptable to the Stockholder in form and substance. For the avoidance of doubt, the
Stockholder shall not (x) be obligated to provide any representations or warranties in connection with the Merger, (y) be liable for indemnification, if any, in such Merger or for the inaccuracy of any representations and warranties made
by the Company in connection with such Merger, other than on a basis which is several and not joint or (z) take any other actions in connection with the Merger other than rendering its Series A Preferred, Series B Preferred and Common Stock for
exchange in the Merger. 
 In the event that subsequent to the date hereof there are (i) any material
changes to the terms of the Merger or the Merger Term Sheet, (ii) there are any material changes to the Merger Documents in the form approved by the Stockholders or (iii) the Company waives any material representations, warranties or
closing conditions contained in the merger agreement with Kopr, the consent set forth in Section 2(a) above shall be void and the Company shall be obligated to re-solicit the Consent of the Stockholders. 

3. TRANSFER OF SECURITIES AND VOTING RIGHTS.

 (a) Restriction on Transfer of Securities. Subject to Section 3(c) below, during
the period from the date of this Agreement through the Expiration Date, Stockholder shall not, directly or indirectly, cause or permit any Transfer of any of the Stockholder’s shares of the Company’s capital stock. 

(b) Restriction on Transfer of Voting Rights. During the period from the date of this Agreement through the
Expiration Date, Stockholder shall ensure that (a) none of its shares of the Company’s capital stock is deposited into a voting trust and (b) no proxy is granted, and no voting agreement or similar agreement is entered into, with
respect to any of such shares of capital stock. 
 (c) Permitted Transfers.
Section 3(a) above shall not prohibit a transfer of Company Common Stock by Stockholder (i) to any member of Stockholder’s immediate family, or to a trust for the benefit of Stockholder and/or any member of Stockholder’s
immediate family, (ii) upon the death of Stockholder, (iii) if Stockholder is a corporation, partnership or limited liability company, to one or more shareholders, partners or members of Stockholder or to an affiliated corporation under
common control with Stockholder or (iv) to any affiliate of Stockholder; provided, however, that a transfer referred to in this sentence shall be permitted 

  
 2 

 
only if, as a precondition to such transfer, the transferee agrees in writing, in a form reasonably satisfactory to the Company, to be bound by the terms of this Agreement. 

4. DEFINITIONS. 
 (a) “Expiration Date” shall mean the date which is the earliest to occur of (i) immediately following the consummation of the Merger,
(ii) August 15, 2011 or (iii) abandonment of the Merger by the Company or Kopr. The Company will notify the Stockholder immediately if the Company or Kopr abandons the Merger. 

(b) A Stockholder shall be deemed to have a effected a “Transfer” of a security if such
Stockholder directly or indirectly (i) sells, pledges, encumbers, grants an option with respect to, transfers or disposes of such security or any interest in such security or (ii) enters into an agreement or commitment contemplating the
possible sale of, pledge of, encumbrance of, grant of an option with respect to, transfer of or disposition of such security or any interest therein. 
 5. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER. Stockholder hereby represents and warrants to the Company as
follows: 
 (a) Authorization, etc. Stockholder has the power and authority to execute and
deliver this Agreement and to perform his or its obligations hereunder and thereunder. This Agreement has been duly executed and delivered by Stockholder and constitutes a legal, valid and binding obligation of Stockholder, enforceable against
Stockholder in accordance with its terms, subject to (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors and (ii) rules of law governing specific performance, injunctive relief and other equitable
remedies. If Stockholder is an entity, then Stockholder is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was organized. 

(b) No Conflicts or Consents. The execution and delivery of this Agreement by Stockholder does not, and the
performance of this Agreement by Stockholder will not (i) conflict with or violate any law, rule, regulation, order, decree or judgment applicable to Stockholder or (ii) require any consent or approval of any other person or entity.

 (c) Stockholder represents that it is an “accredited investor” (see Appendix 1 hereto)
within the meaning of Regulation D under the Securities Act. 
 6. MISCELLANEOUS. 

(a) Registration Rights. The registration rights set forth in Appendix 2 attached hereto shall apply
to all of the Registrable Securities (as defined in Appendix 2) held by the Stockholder as of the date hereof or issued as part of the Dividend. The Company represents to the Stockholder that the registration rights set forth in Appendix
2 attached hereto are at least as favorable as those offered to the purchasers of the Company’s Series C Preferred Stock. The Company further covenants to the Stockholder that it will not provide to the holders of the Series C Preferred
Stock registration rights that are more favorable than those offered to the Stockholder, without offering such rights to the Stockholder. 

  
 3 

 (b) Expenses. All costs and expenses incurred in connection
with the transactions contemplated by this Agreement shall be paid by the party incurring such costs and expenses. 
 (c) Notices. Any notice or other communication required or permitted to be delivered to either party under this Agreement shall be in writing and shall be deemed properly delivered, given
and received when delivered (by hand, by registered mail, by courier or express delivery service or by facsimile) to the address set forth beneath the name of such party below (or to such other address as such party shall have specified in a written
notice given to the other party): 
 if to Stockholder: 

at the address set forth on the signature page hereof; and 

if to the Company: 
 45 Rockefeller Plaza, Suite 2000 
 New York, NY, 10111 

Attn: Chief Executive Officer 
 (d) Entire Agreement. This Agreement sets forth the entire understanding of the parties relating to the subject matter hereof and supersedes all prior agreements and understandings among or
between Stockholder and the Company relating to the subject matter hereof. 
 (e) Severability. If
any provision of this Agreement or any part of any such provision is held under any circumstances to be invalid or unenforceable in any jurisdiction, then (i) such provision or part thereof shall, with respect to such circumstances and in such
jurisdiction, be deemed amended to conform to applicable laws so as to be valid and enforceable to the fullest possible extent, (ii) the invalidity or unenforceability of such provision or part thereof under such circumstances and in such
jurisdiction shall not affect the validity or enforceability of such provision or part thereof under any other circumstances or in any other jurisdiction and (iii) such invalidity or enforceability of such provision or part thereof shall not
affect the validity or enforceability of the remainder of such provision or the validity or enforceability of any other provision of this Agreement. Each provision of this Agreement is separable from every other provision of this Agreement, and each
part of each provision of this Agreement is separable from every other part of such provision. 
 (f)
Governing Law. This Agreement shall be construed in accordance with, and governed in all respects by, the laws of the State of New York (without giving effect to principles of conflicts of laws). The parties submit to the exclusive
jurisdiction of the state and federal courts located in New York County, New York for any action, suit or proceeding arising out of this Agreement. 
 (g) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to a party hereto or to their heirs,

  
 4 

 
personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable. If
any party hereto or his heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense
therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

(h) Assignment; Binding Effect. Except as provided herein, neither this Agreement nor any of the interests
or obligations hereunder may be assigned or delegated by Stockholder, and any attempted or purported assignment or delegation of any of such interests or obligations shall be void. Subject to the preceding sentence, this Agreement shall be binding
upon Stockholder and his heirs, estate, executors and personal representatives and his or its successors and assigns, and shall inure to the benefit of the Company and its successors and assigns. Without limiting any of the restrictions set forth in
Section 3 hereof (or elsewhere in this Agreement), this Agreement shall be binding upon any person or entity to whom any of Stockholder’s shares of the Company’s capital stock are transferred. Nothing in this Agreement is intended to
confer on any person or entity (other than the Company and its successors and assigns) any rights or remedies of any nature. 
 (i) Waiver. No failure on the part of the Company to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of the Company in exercising any power,
right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise
thereof or of any other power, right, privilege or remedy. The Company shall not be deemed to have waived any claim available to the Company arising out of this Agreement, or any power, right, privilege or remedy of the Company under this Agreement,
unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of the Company; and any such waiver shall not be applicable or have any effect except in the
specific instance in which it is given. 
 (j) Jury Trial. STOCKHOLDER IRREVOCABLY WAIVES THE RIGHT TO A JURY
TRIAL IN CONNECTION WITH ANY LEGAL PROCEEDING RELATING TO THIS AGREEMENT OR THE ENFORCEMENT OF ANY PROVISION OF THIS AGREEMENT. 
 [REMAINDER OF THIS PAGE INTENTIONALLY BLANK] 

  
 5 

 IN WITNESS WHEREOF, Stockholder has
caused this Agreement to be executed as of the date set forth below. 
 STOCKHOLDER: 

Name of Stockholder: 
 ___________________________________________ 
 Signature:
__________________________________ 
 Name and Title (if Stockholder is an entity): 

Address: ___________________________________ 
 Date: ______________________________________ 
 Acknowledged and Agreed:

 COMPANY: 
 By: _______________________________________ 
 Name:
____________________________________ 
 Title: _____________________________________ 

 

 EXHIBIT A 
 STOCKHOLDER RESOLUTIONS 
 AMENDMENT OF
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 
 WHEREAS, the Company’s Board of Directors has approved, subject to stockholder approval, an amendment to the Company’s Amended and Restated Certificate of Incorporation, as
modified by that certain Certificate of Designation, Preferences and Rights of the Series B Preferred Stock (the “Current Certificate”) to (i) eliminate the Special Dividend set forth in Article IV.E,
Section 1(a) of the Current Certificate and (ii) restate the automatic conversion provision applicable to the Company’s Series A Preferred Stock, set forth in Article IV.E, Section 5(j) of the Current Certificate which, in turn,
is applicable to the Company’s Series B Preferred Stock (the “Series B Preferred”) in accordance with the terms of the Series B Preferred. 
 RESOLVED, that effective and contingent upon the payment of the Dividend (as defined in the Consent and Support Agreement to which these resolutions are attached as Exhibit A) the
First Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company, in substantially the form attached hereto as Exhibit A-1 (the “Certificate of Amendment”) be, and it hereby is,
adopted and approved in all respects; 
 RESOLVED FURTHER, that the officers of the Company
be, and each of them hereby is, authorized and directed to execute the Certificate of Amendment on behalf of the Company and to file the Certificate of Amendment with the Delaware Secretary of State in the form and manner as required by the laws of
the State of Delaware; and 
 RESOLVED FURTHER, that the officers of the Company be, and
each of them hereby is, authorized and directed, for and on behalf of the Company, to take such further actions and execute such documents as may be necessary in order to implement the foregoing resolutions. 

 EXHIBIT A-1 
 CERTIFICATE OF AMENDMENT 

 APPENDIX 1 
 The term “accredited investor” includes: 
  

	 	•	 	 an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with his or her spouse, presently exceeds
$1,000,000; 

 Explanation: In calculating net worth you may include equity in personal property and real estate, excluding
your principal residence, cash, short-term investments, stock and securities. Equity in personal property and real estate should be based on the fair market value of such property minus debt secured by such property. 

 

	 	•	 	 an individual (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two most recent years, or joint income with
his or her spouse in excess of $300,000 in each of those years (in each case, including foreign income, tax exempt income and full amount of capital gains and losses, but excluding any income of other family members and any unrealized capital
appreciation), and has a reasonable expectation of reaching the same income level in the current year; 

  

	 	•	 	 either: (a) a bank as defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the “Act”); (b) a
savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act, whether acting in its individual or fiduciary capacity; (c) a broker dealer registered pursuant to Section 15 of the Securities Exchange
Act of 1934; (d) an insurance company as defined in Section 2(a)(13) of the Act; (e) an investment company registered under the Investment Company Act of 1940, as amended (the “Investment Company Act”) or a business
development company as defined in Section 2(a)(48) of the Investment Company Act; (f) a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business
Investment Act of 1958; (g) a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such a plan has total assets
in excess of $5,000,000; or (h) an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), if the investment decision is made by a plan fiduciary, as defined in
Section 3(21) of ERISA, which is either a bank, savings and loan association, insurance company or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000, or, if a self-directed plan, with
investment decisions made solely by persons that are accredited investors, as defined in Rule 501(a) promulgated under the Act; 

  

	 	•	 	 a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940, as amended;

  

	 	•	 	 an organization within the meaning of Section 501(c)(3) of the Internal Revenue Code, a corporation, a Massachusetts or similar business trust, or
a partnership, not formed for the specific purpose of acquiring the Company’s securities, with total assets in excess of $5,000,000; 

  

	 	•	 	 a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Company’s securities, whose investments
are directed by a “sophisticated person” as described in Rule 506(b)(2)(ii) promulgated under the Act; 

  

	 	•	 	 an entity, all the equity owners of which are “accredited investors” within one or more of the above categories; or

  

	 	•	 	 a director or executive officer of the Company. 

 APPENDIX 2 

RESALE REGISTRATION RIGHTS 
 Except as set forth herein, all of the terms and conditions in (a) the letter agreements dated January 7, 2010 between the Company and the Holders of Series A Preferred Stock and Series B
Preferred Stock of Asphelia Pharmaceuticals, Inc. and (b) the registration rights sections in each of the subscription agreements between the Company and the Stockholder, shall continue to apply with respect to the Registrable Securities
covered by the applicable agreement. All defined terms used, but not otherwise defined, herein shall have the respective meanings ascribed to them in the Consent and Support Agreement dated as of April __, 2011. 

1.1 Definitions. As used in this Appendix 2, the following terms shall have the following meanings. 

(a) The term “Company” shall mean Coronado Biosciences, Inc. 

(b) The term “Holder” shall mean any holder of Registrable Securities. 

(c) The term “IPO” shall mean an initial offering of the Company’s securities to the public pursuant
to an effective registration statement under the Securities Act. 
 (d) The terms “register”,
“registered” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or order of
effectiveness of such registration statement or document. 
 (e) The term “Registrable
Securities” shall mean (i) the shares of common stock issuable upon the conversion of the preferred stock of the Company (or any successor security) then held by the Holder; and (ii) any shares of equity securities issuable (or
issuable upon the conversion or exercise of any warrant, right or other security that is issued) pursuant to a dividend (including, without limitation, the Dividend) or other distribution with respect to or in replacement of any Securities;
provided, however, that securities shall only be treated as Registrable Securities if and only for so long as they (A) have not been disposed of pursuant to a registration statement declared effective by the SEC; (B) have not been sold in
a transaction exempt from the registration and prospectus delivery requirements of the Securities Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale; (C) are held by
a Holder or a permitted transferee of a Holder pursuant to Section 1.11; or (D) may not be disposed of by the Holder under Rule 144 under the Securities Act without restriction including public information requirements. 

(f) The term “Trading Event” means the first date on which the Company’s Common Stock trades on a
national securities exchange or an Over-the-Counter Bulletin Board. 
 1.2 Resale Registration. In addition to the
existing registration rights of the Stockholder, within 60 days of the earlier to occur of (i) the first day that shares of the Company’s capital stock are registered pursuant to Section 12 of the Exchange Act or (ii) the
effective date of the Merger, (the date of the earlier of (i) or (ii) to occur referred to herein as the “Public Date”), the Company shall file a resale registration statement covering the resale of all of the Registrable
Securities (or less than all, if the Company is limited in the number of shares that it can include on such resale registration statement by regulation or the requirements of any exchange), and use its reasonable best efforts to have the
registration statement declared effective within 120 days after the Public Date. 

  
 10 

 1.3 Registration Procedures. In connection with the registration rights included in
this Appendix 2, the Company shall, as expeditiously as reasonably possible: 
 (a) Use reasonable best
efforts to (i) cause such registration statement to become effective, and (ii) cause such registration statement to remain effective in accordance with Section 1.12 hereof. The Company will also use its reasonable best efforts to,
during the period that such registration statement is required to be maintained hereunder, file such post-effective amendments and supplements thereto as may be required by the Securities Act and the rules and regulations thereunder or otherwise to
ensure that the registration statement does not contain any untrue statement of material fact or omit to state a fact required to be stated therein or necessary to make the statements contained therein, in light of the circumstances under which they
are made, not misleading; provided, however, that if applicable rules under the Securities Act governing the obligation to file a post-effective amendment permits, in lieu of filing a post-effective amendment that (i) includes any
prospectus required by Section 10(a)(3) of the Securities Act or (ii) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the Company may incorporate by
reference information required to be included in (i) or (ii) above in the preceding sentence to the extent such information is contained in periodic reports filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”) in the registration statement. In the event that the Company becomes qualified for the use of Form S-3 or any successor form at a time when any registration statement on any other Form which includes
Registrable Securities is required to be maintained hereunder, the Company shall, upon the request of any Holder, subject to Section 1.4, (i) as expeditiously as reasonably possible, use commercially reasonable efforts to cause a
Short-Form Registration covering such Registrable Securities to become effective and (ii) comply with each of the other requirements of this Section 1.3 which may be applicable thereto. Upon the effectiveness of such Short-Form
Registration, the Company shall be relieved of its obligations hereunder to keep in effect the registration statement which initially covered the Registrable Securities included in such Short-Form Registration. 

(b) Prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used
in connection with such registration statement, as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. 

(c) Furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus as amended
or supplemented from time to time, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d) Use reasonable best efforts to register and qualify the securities covered by such registration statement under the
state securities laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the managing underwriter of such offering. Each selling Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

  
 11 

 (f) Notify each Holder of Registrable Securities covered by such
registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, (i) when the registration statement or any post-effective amendment and supplement thereto has become effective;
(ii) of the issuance by the SEC of any stop order or the initiation of proceedings for that purpose (in which event the Company shall make every effort to obtain the withdrawal of any order suspending effectiveness of the registration statement
at the earliest possible time or prevent the entry thereof); (iii) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities for sale in any jurisdiction or the
initiation of any proceeding for such purpose; and (iv) of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing (and each Holder agrees to suspend any trading under the Registration Statement until such
condition is abated). 
 (g) Cause all such Registrable Securities registered hereunder to be listed on each
securities exchange or quotation service on which similar securities issued by the Company are then listed or quoted or, if no such similar securities are listed or quoted on a securities exchange or quotation service, apply for qualification and
use reasonable best efforts to qualify such Registrable Securities for inclusion on a national securities exchange or the Over-the-Counter Bulletin Board. 
 (h) Provide a transfer agent and registrar for all Registrable Securities registered hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of
such registration. 
 (i) Cooperate with the selling Holders and the managing underwriters, if any, to facilitate
the timely preparation and delivery of certificates representing the Registrable Securities to be sold, which certificates will not bear any restrictive legends; and enable such Registrable Securities to be in such denominations and registered in
such names as the managing underwriters, if any, shall request at least two business days prior to any sale of the Registrable Securities to the underwriters. 
 1.4 Furnish Information. It shall be a condition precedent to the obligation of the Company to take any action pursuant to this Appendix 2 with respect to the Registrable Securities of any
Holder that such Holder shall furnish to the Company such information regarding the Holder, the Registrable Securities held by the Holder, and the intended method of disposition of such securities as shall be reasonably required by the Company to
effect the registration of such Holder’s Registrable Securities. 
 1.5 Registration Expenses. The Company shall
bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to registrations pursuant to Section 1.2 for each Holder, including (without limitation) all registration,
filing, and qualification fees, printers and accounting fees relating or apportionable thereto (“Registration Expenses”), but excluding underwriting discounts and commissions relating to Registrable Securities and excluding any
professional fees or costs of accounting, financial or legal advisors to any of the Holders. 
 1.6 Underwriting
Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital stock, if the total amount of securities, including Registrable Securities, requested by Holders to be included in such offering
exceeds the amount of securities sold that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such Registrable
Securities which the underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling Holders according to

  
 12 

 
the total amount of securities entitled to be included therein owned by each selling Holder or in such other proportions as shall mutually be agreed to by such selling Holders). For purposes of
the preceding parenthetical concerning apportionment, for any selling Holder who is a holder of Registrable Securities and is a partnership or corporation, the partners, retired partners and stockholders of such Holder, or the estates and family
members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling Holder,” and any pro-rata reduction with respect to such “selling Holder”
shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling Holder,” as defined in this sentence. 

1.7 Rule 415 Requirements. Notwithstanding the registration obligations set forth in Section 1.2, in the event the SEC
informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale on a single registration statement, the Company agrees to promptly (i) inform each of the Holders thereof,
(ii) file amendments to the registration statement as required by the SEC and/or (iii) withdraw the registration statement and file a new registration statement (a “New Registration Statement”), in either case covering the
maximum number of Registrable Securities permitted to be registered by the SEC, on Form S-1 or such other form available to register for resale the Registrable Securities as a secondary offering; provided, however, that prior to filing such
amendment or New Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the SEC for the registration of all of the Registrable Securities in accordance with the SEC guidance, including
without limitation, the Manual of Publicly Available Telephone Interpretations D.29. In the event the Company amends the registration statement or files a New Registration Statement, as the case may be, under clauses (ii) or (iii) above,
the Company will file with the SEC, as promptly as allowed by the SEC or by SEC guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-1 or such other form available to register for
resale those Registrable Securities that were not registered for resale on the registration statement, as amended, or the New Registration Statement and cause such registration statement to be declared effective by the SEC. The foregoing
notwithstanding, if the Company is required to limit the number of shares that it can include on such resale registration statement or New Registration Statement by regulation or the requirements of the SEC or any exchange, then, notwithstanding any
other registration rights of the Holder, the number of Registrable Securities to be included on such registration statement and New Registration Statement shall be allocated to the Holders on a pro rata basis based on the number of
Registrable Securities held by all Holders. 
 1.8 Delay of Registration. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Appendix 2. 

1.9 Indemnification. In the event that any Registrable Securities are included in a registration statement under this Appendix
2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any
underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint
or several) to which they may become subject under the Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus
contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any
violation or alleged violation by the Company of the Securities Act, the Exchange 

  
 13 

 
Act, or any rule or regulation promulgated under the Securities Act, or the Exchange Act, and the Company will pay to each such Holder, underwriter or controlling person, as incurred, any legal
or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 1.9(a) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case
for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such
registration by any such Holder, underwriter or controlling person or a violation of any provision of this Appendix 2 by a Holder. 
 (b) To the extent permitted by law, each Selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers, each person, if any, who controls the Company within the
meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or
several) to which any of the foregoing persons may become subject, under the Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation,
in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration or a violation of any
provision of this Appendix 2 by a Holder; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 1.9(b), in connection with
investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 1.9(b) shall not apply to amounts paid in settlement of any such loss, claim,
damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, further, that, in no event shall any indemnity under this Section 1.9(b)
exceed the cash value of the net proceeds from the offering received by such Holder. 
 (c) Promptly after
receipt by an indemnified party under this Section 1.9 of notice of the commencement of any action (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party
under this Section 1.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any
other indemnifying party similarly notified, to assume the defense thereof with counsel selected by the indemnifying party and approved by the indemnified party (whose approval shall not be unreasonably withheld); provided, however, that an
indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability
to the indemnified party under this Section 1.9, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.9.

 (d) If the indemnification provided for in this Section 1.9 is held by a court of competent jurisdiction
to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such 

  
 14 

 
indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is
appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such
statement or omission. Notwithstanding the foregoing, in no event shall the amount of any contribution under this Section 1.9(d) exceed the cash value of the net proceeds from the offering received by such Holder 

(e) The obligations of the Company and Holders under this Section 1.9 shall survive the completion of any offering of
Registrable Securities in a registration statement under this Appendix 2, and otherwise. 
 1.10 Reports Under
Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to: 
 (a) file Form 10 information as
promptly as practicable after the Reverse Merger in accordance with Rule 144(i). 
 (b) make and keep public
information available, as those terms are understood and defined in Rule 144, at all times after 90 days after the effective date of the IPO or Trading Event by the Company; 

(c) file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act
and the Exchange Act; and 
 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities,
forthwith upon request (i) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (ii) such other information as may be reasonably requested in availing any
Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
 1.11 Permitted Transferees. The rights to cause the Company to register Registrable Securities granted to the Holders by the Company under this Appendix 2 may be assigned in full by a Holder
in connection with a transfer by such Holder of its Registrable Securities if: (a) such transfer is otherwise effected in accordance with applicable securities laws and any agreement between the Company and the Holder; and (b) such Holder
transfers at least 51% of its shares of Registrable Securities to the transferee. Except as specifically permitted by this Section 1.11, the rights of a Holder with respect to Registrable Securities as set out herein shall not be transferable
to any other Person, and any attempted transfer of such registration rights shall by void. 
 1.12 Termination of
Registration Rights. The right of any Holder to request or demand inclusion in any registration pursuant to Section 1.2 shall terminate if all Registrable Securities held by such Holder may immediately be sold under Rule 144 without
restriction, including public information requirements. 

  
 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]